Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
C1 inhibitor (human) (Cinryze®) is recommended as an option for use within NHS Wales for the treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE); routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment. |
|||
|
|||
Medicine details |
|||
| Medicine name | c1 inhibitor (human) (Cinryze®) | ||
| Formulation | 500 international units / 5ml powder and solvent for solution for injection | ||
| Reference number | 3295 | ||
| Indication | Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE); routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment |
||
| Company | Shire Pharmaceuticals Ltd | ||
| BNF chapter | Respiratory system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2117 | ||
| NMG meeting date | 06/09/2017 | ||
| AWMSG meeting date | 11/10/2017 | ||
| Date of issue | 19/10/2017 | ||
| Date of last review | October 2020 | ||